Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease

Journal of the National Medical Association

Volumn 103, Issue 6, 2011, Pages 524-533

  Vaziri, Nosratola D ^a   Navab, Kaveh ^b   Gollapudi, Pavan ^a   Moradi, Hamid ^a   Pahl, Madeleine V ^a   Barton, Cyril H ^a   Fogelman, Alan M ^b   Navab, Mohamad ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular; Drugs; Inflammation; Kidney; Lipids

Indexed keywords

ARYLDIALKYLPHOSPHATASE; GLUTATHIONE PEROXIDASE; HEPARIN; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; AUTACOID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHEMOTAXIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEPARINIZATION; HUMAN; INFLAMMATION; KIDNEY FAILURE; MALE; MONOCYTE; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; COMPARATIVE EFFECTIVENESS; LIPID PEROXIDATION; METABOLISM; MIDDLE AGED; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; UREMIA;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; ATHEROSCLEROSIS; CHOLESTEROL, HDL; COMPARATIVE EFFECTIVENESS RESEARCH; FEMALE; HEPARIN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LIPID PEROXIDATION; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; RENAL DIALYSIS; UREMIA;

EID: 80052352028     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)30368-0     Document Type: Article

References (46)

1. Excerpts from the US Renal Data system 2005 Annual Data Report. Atlas of end-stage renal disease in the United States. Am J Kidney Dis. 2006;47:S1-S286.
2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296-1305.
3. Kovesdy CP, Trivedi BK, Anderson JE. Associations of kidney function with mortality in patients with chronic kidney disease not yet on dialysis: a historical prospective cohort study. Adv Chronic Kidney Dis. 2006;13:183-188.
4. Muntner P, He J, Astor BC, et al. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J Am Soc Nephrol. 2005;16:529-538. (Pubitemid 41725151)
5. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int. 2002;62:1524-1538. (Pubitemid 35286260)
6. McCullough PA. Why is chronic kidney disease the "spoiler" for cardiovascular outcomes? J Am Coll Cardiol. 2003;41:725-728. (Pubitemid 36308376)
7. Stenvinkel P, Alvestrand A. Inflammation in end-stage renal disease: Sources, consequences, and therapy. Semin Dial. 2002;15:329-337.
8. Vaziri ND. Dyslipidemia of chronic renal failure: The nature, mechanisms and potential consequences. Am J Physiol, Renal Physiol. 2006;290:262-272.
9. Vaziri ND. Oxidative stress in chronic renal failure: The nature, mechanism and consequences. Semin Nephrol. 2004;24:469-473.
10. Vaziri ND, Bai Y, Ni Z, Quiroz Y, et al. Intra-renal angiotensin II/AT1 receptor, oxidative stress, inflammation, and progressive injury in renal mass reduction. J Pharmacol Exp Ther. 2007;323:85-93. (Pubitemid 47443257)
11. Botham KM, Moore EH, De Pascale C, et al. The induction of macrophage foam cell formation by chylomicron remnants. Biochem Soc Trans. 2007;35:454-458. (Pubitemid 46975050)
12. Gleissner CA, Leitinger N, Ley K. Effects of native and modified low-density lipoproteins on monocyte recruitment in atherosclerosis. Hypertension. 2007;50:276-283. (Pubitemid 47205770)
13. Hansson GK, Robertson AK, Söderberg-Nauclér C. Inflammation and atherosclerosis. Annu Rev Pathol. 2006;1:297-329.
14. Obryshev YV. Monocyte recruitment and foam cell formation in atherosclerosis. Micron. 2006;37:208-222.
15. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005;11:3061-3072. (Pubitemid 41158090)
16. Wilensky RL, Hamamdzic D. The molecular basis of vulnerable plaque: potential therapeutic role for immunomodulation. Curr Opin Cardiol. 2007;22:545-551. (Pubitemid 47542241)
17. Ansell BJ, Navab M, Hama S, et al. Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-denisty lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation. 2003;108:2751-2756. (Pubitemid 37498976)
18. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Bio.l 2003;23:1724-1731. (Pubitemid 37254854)
19. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardio. 2007;100:n32-n40.
20. Feig JE, Shamir R, Fisher EA. Atheroprotective effects of HDL: beyond reverse cholesterol transport. Curr Drug Targets. 2008;9:196-203. (Pubitemid 351843600)
21. Navab M, Imess SS, Hama SY, et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest. 1991;88:2039-2046.
22. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995;96:2882-2891.
23. Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia-relation to renal function and dialysis. Nephrol. 1991;57:401-410.
24. Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease [published ahead of print]. Nat Rev Nephrol. 2010: 6:287-296.
25. Kamanna VS, Kashyap ML, Pai R, et al. Uremic serum subfraction inhibits apolipoprotein A-I production by a human hepatoma cell line. J Am Soc Nephrol. 1994;5:193-200. (Pubitemid 24977075)
26. Shah GM, Lin ZL, Kamanna VS, et al. Effect of serum subfractions from peritoneal dialysis patients on Hep-G2 cell apolipoprotein A-I and B metabolism. Kidney Int. 1996;50:2079-2087. (Pubitemid 26417553)
27. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14:1462- 1466.
28. Kalantar-Zadeh K, Kopple JD, Kamranpour N, et al. HDL-inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 2007;72:1149-1156. (Pubitemid 47609043)
29. Moradi H, Pahl MV, Elahimehr R, et al. Impaired Antioxidant Activity of HDL in Chronic Kidney Disease. Transl Res. 2009;153:77-85.
30. Vaziri ND, Moradi H, Pahl MV, et al. In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide. Kidney Int. 2009;76:437-44.
31. Kim HJ, Moradi H, Yuan J, et al. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol, Renal Physiol. 2009;296:F1297-1306.
32. Moradi H, YuanJ, Ni Z, et al. Reverse cholesterol pathway in experimental chronic kidney disease. Am J Nephrol. 2009;30:147-154.
33. Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928-1935. (Pubitemid 26417536)
34. Vaziri ND, Wang XQ, Liang K. Secondary hyperparathyroidism downregulates lipoprotein lipase expression in chronic renal failure. Am J Physiol Renal Physiol. 1997;273:F925-F930. (Pubitemid 28113028)
35. Vaziri, ND, Liang K. Down regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int. 1997;51:913-919. (Pubitemid 27157982)
36. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase, hepatic lipase and VLDL receptor in focal glomeruloscleros. Kidney Int. 2003;64:1780-1786. (Pubitemid 37323707)
37. Kim C, Vaziri, ND. Downregulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int. 2005;67:1028-1032. (Pubitemid 41623326)
38. Vaziri ND, Liang K, Parks JS. Downregulation of hepatic lecithin:cholesterol acyltransferase (LCAT) gene expression in chronic renal failure. Kidney Int. 2001;59:2192-2196. (Pubitemid 32467611)
39. Liang K, Vaziri ND. Upregulation of Acyl-CoA: Cholesterol acyltransferase (ACAT) in chronic renal failure. Am J Physiol: Endocrine and Metab. 2002;283: E676-E681.
40. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol, Renal Physiol. 2004;287:F1038-F1043. (Pubitemid 39391101)
41. Van Lenten BJ, Reddy ST, Navab M, et al. Understanding changes in high density lipoproteins during the acute phase response. Arterioscler Thromb Vasc Biol. 2006;26:1687-1688. (Pubitemid 44305319)
42. Gugliucci A, Mehlhaff K, Kinugasa E, et al. Paraoxonase-1 concentrations in end-stage renal disease patients increase after hemodialysis: correlations with low molecular AGE adduct clearance. Clin Chim Acta. 2007;377:213-220. (Pubitemid 44920216)
43. Myrmel T, Larsen TS, Reikerås O. Lipolytic effect of low-molecularweight- heparin (Fragmin®) and heparin/dihydroergotamine in thromboprophylactic doses during total hip replacement. Scandinavian Journal of Clin Lab Invest. 1992;52:741-745.
44. Albertini R, Rindi S, Passi A, et al. The effect of heparin on Cu(2+)- mediated oxidation of human low-density lipoproteins. FEBS Lett. 1995;377(2):240-242.
45. Sandström J, Carlsson L, Marklund SL, et al. The heparin-binding domain of extracellular superoxide dismutase C and formation of variants with reduced heparin affinity. J Biol Chem. 1992;267:8205-18209.
46. Sela S, Shurtz-Swirski R, Shapiro G, et al. Oxidative stress during hemodialysis: effect of heparin. Kidney Int Suppl.2001;78:S159-S163 (Pubitemid 32144090)